Last updated: 2026-09-08 15:49:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
PDS Biotechnology Corporation (PDSB) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.28, with a market capitalization of $12.31M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.20 to $1.55. This page covers its latest market performance, valuation, price trends and company information.
$12.31M | |
$0.49 | |
$17.85 | |
$0.20 | |
$0.22 | |
394.41M | |
1.28M | |
-- | |
$1.55 | |
$0.20 | |
-- | |
-- |
PDS Biotechnology Corporation (PDSB) is currently trading at $0.28 as of 2026-09-08 15:32:28, up 26.82% ($0.06) from the previous close of $0.22
During today's regular trading session, PDSB has traded between $0.20 and $17.85, with a trading volume of 394.41M shares. The current price is near the lower end of today's range.
Over the past seven days, PDS Biotechnology Corporation (PDSB) moved from $0.22 to $0.28, representing a gain of 28.04% ($0.06).
The stock traded between $0.20 and $0.64 during the period. The latest price is near the lower end of the 7-day range, indicating strong upward.
The average daily volume was 960.18 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 6.2%
PDSB is currently trading at $0.28, placing it 6.2% of the way from its 52-week low of $0.20 to its 52-week high of $1.55. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 21 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of PDS Biotechnology Corporation (PDSB) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.